Evaluation of clinical response to neoadjuvant chemotherapy of breast cancers-contrast-enhanced ultrasound versus contrast-enhanced magnetic resonance imaging

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100042547

Enrollment

Unknown

Registered

2021-01-23

Start date

2021-01-11

Completion date

Unknown

Last updated

2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:Pathological results.

Index test:1.&#32

cancers-contrast-enhanced&#32

ultrasound&#32

(CEUS)

2.&#32

contrast-enhanced&#32

magnetic&#32

resonance&#32

imaging&#32

(ceMRI).

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with confirmed breast cancer, clinical staging II or III; 2.Patients who are scheduled to NAC; 3.Patients who are scheduled to breast surgery after NAC; 4.Patients without any history of treatment for breast cancer before NAC; 5.Patients who are willing to undergo CEUS examination and ceMRI.

Exclusion criteria

Exclusion criteria: 1.Patients are pregnant or lactating; 2.Patients undergo open surgical biopsy for breast cancer diagnosis; 3.Patients with any contraindications to NAC, CEUS examination or ceMRI; 4.Other reasons that the combined clinician considers not suitable for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Tumor diameter;consistency;	—

Secondary

Measure	Time frame
IMAX;RT;TTP;mTT;	—

Countries

China

Contacts

Public ContactYulan Peng

West China Hospital of Sichuan University

yulanpeng@126.com+86 18980601606

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026